We evaluated PD-L1 expression using highly sensitive quantitative immunohistochemistry with fluorescent nanoparticles (PIDs) in 155 patients with unresectable, recurrent, or metastatic cancer treated with ICIs, and compared it with that using the conventional IHC-DAB method. The gene discussed is CD274; the disease is metastatic malignant neoplasm.